1. Home
  2. CLDX vs SII Comparison

CLDX vs SII Comparison

Compare CLDX & SII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Celldex Therapeutics Inc.

CLDX

Celldex Therapeutics Inc.

SELL

Current Price

$27.73

Market Cap

3.0B

Sector

Health Care

ML Signal

SELL

Logo Sprott Inc.

SII

Sprott Inc.

SELL

Current Price

$108.25

Market Cap

3.0B

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
CLDX
SII
Founded
N/A
2008
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.0B
IPO Year
1995
2011

Fundamental Metrics

Financial Performance
Metric
CLDX
SII
Price
$27.73
$108.25
Analyst Decision
Strong Buy
Analyst Count
15
0
Target Price
★ $63.07
N/A
AVG Volume (30 Days)
★ 2.1M
86.5K
Earning Date
11-09-2026
11-04-2026
Dividend Yield
N/A
★ 1.42%
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $12,743,000.00
N/A
Revenue This Year
$19.74
$35.89
Revenue Next Year
$438.11
N/A
P/E Ratio
★ N/A
$63.42
Revenue Growth
★ 87.78
N/A
52 Week Low
$22.10
$78.79
52 Week High
$45.14
$169.63

Technical Indicators

Market Signals
Indicator
CLDX
SII
Relative Strength Index (RSI) 29.14 33.14
Support Level $22.39 $102.24
Resistance Level $32.16 $111.40
Average True Range (ATR) 1.26 3.53
MACD -0.12 -0.87
Stochastic Oscillator 1.72 4.04

Price Performance

Historical Comparison
CLDX
SII

About CLDX Celldex Therapeutics Inc.

Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

About SII Sprott Inc.

Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.

Share on Social Networks: